Loxapine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Loxapine |
| DrugBank ID | DB00408 |
| Brand Names (EU) | Adasuve |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | manic bipolar affective disorder | 99.99% | DL |
| 2 | schizophrenia | 99.97% | DL |
| 3 | retinal dystrophy with or without extraocular anomalies | 99.95% | DL |
| 4 | hydranencephaly (disease) | 99.93% | DL |
| 5 | myopia X-linked | 99.93% | DL |
| 6 | congenital disorder of glycosylation with defective fucosylation | 99.92% | DL |
| 7 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 99.92% | DL |
| 8 | myopia 26, X-linked, female-limited | 99.92% | DL |
| 9 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 99.92% | DL |
| 10 | syndromic myopia | 99.92% | DL |
| 11 | atypical glycine encephalopathy | 99.90% | DL |
| 12 | bipolar disorder | 99.84% | DL |
| 13 | major affective disorder | 99.82% | DL |
| 14 | distal 17p13.3 microdeletion syndrome | 99.78% | DL |
| 15 | attention deficit hyperactivity disorder, inattentive type | 99.61% | DL |
| 16 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | 99.61% | DL |
| 17 | anxiety disorder | 99.56% | DL |
| 18 | attention deficit-hyperactivity disorder | 99.49% | DL |
| 19 | Malan overgrowth syndrome | 99.45% | DL |
| 20 | benign paroxysmal torticollis of infancy | 99.42% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.